Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CALQUENCE | AstraZeneca | N-210259 RX | 2017-10-31 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CALQUENCE | AstraZeneca | N-216387 RX | 2022-08-03 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
calquence | New Drug Application | 2022-08-04 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
mantle-cell lymphoma | — | D020522 | C83.1 |
Expiration | Code | ||
---|---|---|---|
ACALABRUTINIB, CALQUENCE, ASTRAZENECA | |||
2026-11-21 | ODE-274 | ||
2024-10-31 | ODE-175 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Acalabrutinib, Calquence, Astrazeneca | |||
9796721 | 2036-07-01 | DS, DP | U-2145, U-2666, U-2667, U-2668, U-2669, U-2670, U-2671 |
10167291 | 2036-07-01 | DP | U-2145, U-2666, U-2667, U-2668, U-2669, U-2670, U-2671 |
10272083 | 2035-01-21 | U-2519, U-2682, U-2683, U-2684, U-2685, U-2686, U-2687 | |
11771696 | 2035-01-21 | U-3710 | |
9290504 | 2032-07-11 | DS, DP | |
9758524 | 2032-07-11 | U-2145 | |
10239883 | 2032-07-11 | U-2666, U-2668 | |
7459554 | 2026-11-24 | DP | |
Acalabrutinib Maleate, Calquence, Astrazeneca | |||
11059829 | 2036-07-01 | DS, DP | U-2145, U-2666, U-2667, U-2668, U-2669, U-2670, U-2671 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 12 | 33 | 9 | 1 | 4 | 50 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Mantle-cell lymphoma | D020522 | — | C83.1 | 9 | 22 | 3 | — | — | 29 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 4 | 10 | 1 | — | — | 12 |
Covid-19 | D000086382 | — | U07.1 | 2 | 2 | 1 | — | 1 | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-hodgkin lymphoma | D008228 | — | C85.9 | 7 | 8 | — | — | — | 10 |
Healthy volunteers/patients | — | — | — | 8 | 2 | — | — | — | 10 |
Waldenstrom macroglobulinemia | D008258 | HP_0005508 | C88.0 | 3 | 8 | — | — | — | 8 |
Follicular lymphoma | D008224 | — | C82 | 4 | 6 | — | — | — | 7 |
Reactive arthritis | D016918 | EFO_0007460 | M02.3 | 3 | 5 | — | — | — | 5 |
B-cell lymphoma | D016393 | — | — | 3 | 3 | — | — | — | 3 |
Multiple myeloma | D009101 | — | C90.0 | 3 | 2 | — | — | — | 3 |
Lymphoma | D008223 | — | C85.9 | 3 | 2 | — | — | — | 3 |
Prolymphocytic leukemia | D015463 | — | — | 2 | 1 | — | — | — | 2 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Biological availability | D001682 | — | — | 2 | — | — | — | — | 2 |
Hepatic insufficiency | D048550 | — | — | 2 | — | — | — | — | 2 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Communicable diseases | D003141 | — | — | 1 | — | — | — | — | 1 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 3 | 3 |
Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | — | — | 1 | 1 |
Drug common name | Acalabrutinib |
INN | acalabrutinib |
Description | Acalabrutinib is a member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a secondary carboxamide, a member of benzamides, a member of pyridines, an aromatic amine, a pyrrolidinecarboxamide, an imidazopyrazine, a ynone and a tertiary carboxamide. |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors Bruton's (Btk) inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12 |
PDB | — |
CAS-ID | 1420477-60-6 |
RxCUI | — |
ChEMBL ID | CHEMBL3707348 |
ChEBI ID | — |
PubChem CID | 71226662 |
DrugBank | DB11703 |
UNII ID | I42748ELQW (ChemIDplus, GSRS) |